Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia-Reference-Cited by-同舟云学术

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia

Published:2018-10-11 Issue:10 Volume:2018 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Hwang Eu Chang¹,Gandhi Shreyas²,Jung Jae Hung³⁴,Imamura Mari⁵,Kim Myung Ha⁶,Pang Ran⁷,Dahm Philipp⁸

Affiliation:

1. Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Department of Urology; Hwasun Korea, South

2. McMaster University; Hamilton ON Canada

3. Yonsei University Wonju College of Medicine; Department of Urology; 20 Ilsan-ro Wonju Gangwon Korea, South 26426

4. Yonsei University Wonju College of Medicine; Institute of Evidence Based Medicine; 20 Ilsan-ro Wonju Gangwon Korea, South 26426

5. University of Aberdeen; Academic Urology; Health Sciences Building Foresterhill Aberdeen UK AB25 2ZD

6. Yonsei University Wonju College of Medicine; Yonsei Wonju Medical Library; Wonju Korea, South

7. Guang An Men Hospital, China Academy of Chinese Medical Sciences; Department of Urology; No.5 Bei Xian Ge Street, Xicheng District Beijing China 100053

8. Minneapolis VA Health Care System; Urology Section; One Veterans Drive Mail Code 112D Minneapolis Minnesota USA 55417

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007360.pub3/epdf/full

Reference104 articles.

1. Comparison of the efficacy of tamsulosin and naftopidil on the quality of life specific to each symptom of the international prostate symptom score: a randomized controlled trial in elderly men with overactive bladder;Fujihara;International Urogynecology Journal and Pelvic Floor Dysfunction,2010

2. Gotoh M Kamihira O Kinukawa T Ono Y Ohshima S Comparison between alpha1A dominant adrenergic receptor antagonist tamsulosin and alpha1D dominant adrenergic receptor antagonist naftopidil for the efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled study (Abstract 271) Joint Meeting of the International Continence Society (ICS) (34th Annual Meeting) and the International Urogynecological Association (IUGA); 2004 August 23-27; Paris 2004

3. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial;Gotoh;British Journal of Urology International,2005

4. Do two alpha 1 adrenergic receptor antagonists with different affinity to alpha 1 subtypes of alpha 1a and alpha 1d make any difference in clinical efficacy in patients with benign prostatic hyperplasia? Randomized controlled trials of naftopidil and tamsulosin;Matsukawa;Journal of Urology,2005

5. Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia;Griwan;Urology Annals,2014

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BIO-ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF FINASTERIDE, TADALAFIL, AND ITS APPLICATION TO PHARMACOKINETIC STUDIES IN RAT PLASMA BY USING LC-MS/MS;International Journal of Applied Pharmaceutics;2024-09-07

2. Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing;BMC Geriatrics;2022-09-28

3. Current and emerging treatment options for premature ejaculation;Nature Reviews Urology;2022-08-25

4. Effect of alpha-adrenoceptor antagonists on sexual function. A systematic review and meta-analysis;Archivio Italiano di Urologia e Andrologia;2022-06-30

5. An approach to exploring patterns of imbalance and potential missingness in reports of the randomized baseline values for primary outcomes measurable at baseline in randomized controlled trials for meta-analyses;BMC Medical Research Methodology;2022-05-28